http://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. Final analysis of the EORTC 10981-22023 AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery?) trial has shown that both axillary lymph node dissection and axillary radiotherapy provide excellent regional control for breast cancer patients with a positive sentinel node biopsy. The AMAROS trial also found that axillary radiotherapy reduces the risk of short term and long-term lymphoedema as compared to axillary lymph node dissection. http://medicalxpress.com/news/2013-06-radiotherapy-surgery-regional-breast-cancer.html Cancer Mon, 03 Jun 2013 06:56:05 EST news289461358 The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent late lumen loss at nine months in the results of an imaging substudy reported at EuroPCR 2013 today. http://medicalxpress.com/news/2013-05-biodegradable-stent-non-inferior-drug-eluting.html Cardiology Tue, 21 May 2013 17:26:46 EST news288376000 (HealthDay)—In acutely ill hospitalized patients, standard-duration rivaroxaban has similar efficacy as enoxaparin in reducing the risk of venous thromboembolism, while extended-duration rivaroxaban has superior efficacy, according to a study published in the Feb. 7 issue of the New England Journal of Medicine. http://medicalxpress.com/news/2013-02-rivaroxaban-noninferior-enoxaparin-acutely-ill.html Diseases, Conditions, Syndromes Thu, 07 Feb 2013 11:20:02 EST news279457844 (HealthDay)—For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 in Diabetes Care. http://medicalxpress.com/news/2013-01-insulin-ly2605541-tops-glargine-glycemic.html Diabetes Sun, 13 Jan 2013 15:30:01 EST news277310415 A increasingly used type of HIV study which involves switching patients on one type of antiretroviral therapy (ART) to another, to see whether the new drug is as good as the at preventing replication of the HIV virus, may be unethical, according to a new Essay published in this week's PLoS Medicine. The studies, termed non-inferiority trials, are only ethical if participants can meaningfully benefit from the treatment change and are more likely to benefit than suffer harm, according to Andrew Carr from the HIV unit in St Vincent's Hospital in Sydney, Australia, Jennifer Hoy from the infectious diseases unit in Alfred Hospital in Melbourne, Australia, and Anton Pozniak from the Chelsea and Westminster Hospital in London, UK. The authors argue in their essay that such trials are not in the best interests of patients, especially as often, these trials have inadequate numbers to assess the key expected benefit and reports all outcomes. http://medicalxpress.com/news/2012-07-trials-involving-hiv-drugs-beneficial.html HIV & AIDS Tue, 17 Jul 2012 17:00:08 EST news261756887 Atrial fibrillation (AF) is the most frequently sustained arrhythmia of the heart. It affects several million people in Europe. AF causes a loss of contraction in the atria and gives rise to heart failure. Moreover, it is associated with a high risk of stroke. One in five strokes is due to AF. http://medicalxpress.com/news/2012-06-atrial-fibrillation-flec-sl-trial-efficacy.html Cardiology Mon, 18 Jun 2012 10:02:06 EST news259232516 Children may perform better in school and feel more confident about themselves if they are told that failure is a normal part of learning, rather than being pressured to succeed at all costs, according to new research published by the American Psychological Association. http://medicalxpress.com/news/2012-03-academic-pressure-children.html Psychology & Psychiatry Mon, 12 Mar 2012 10:48:53 EST news250768124 A clinical trial has established the non-inferiority of a drug-eluting stent with a bioabsorbable polymer compared to a drug-eluting stent with a durable polymer. Results of the EVOLVE clinical trial were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. http://medicalxpress.com/news/2011-11-results-evolve-trial-tct.html Cardiology Fri, 11 Nov 2011 15:17:26 EST news240247032 The second generation drug-eluting stent, everolimus-eluting stent (EES), has consistently demonstrated superior clinical outcomes in randomised controlled trials over the first generation drug-eluting stent, paclitaxel-eluting stent. However, other earlier studies comparing EES with another first generation drug-eluting stent, sirolimus-eluting stent (SES), have only demonstrated the non-inferiority of EES; the superiority of EES relative to SES in terms of target-lesion revascularisation has not yet been investigated in adequately powered randomised controlled trials. http://medicalxpress.com/news/2011-08-clinical-outcomes-pci-patients-sirolimus-eluting.html Cardiology Mon, 29 Aug 2011 11:43:37 EST news233836992